Trial Profile

A multi-center, randomized, partially double-blind, placebo- and active-controlled Phase II study of oral AK3280 in patients with idiopathic pulmonary fibrosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Feb 2026 New trial record
12 Feb 2026 According to Ark Biosciences media release, the company announced that this study is expected to generate critical clinical data to support future regulatory submissions and potential commercialization in the United States and other major markets.
12 Feb 2026 According to Ark Biosciences media release, the company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280 for the treatment of idiopathic pulmonary fibrosis (IPF).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com